| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CNS Pharmaceuticals, Inc.$5.17
-0.16 (-2.91%)
D 22Pipeline Score Overvalued Pharma · Clinical
Market Cap
7.92 M
EPS
-29.63
P/E Ratio
-
Value Trade
125.54 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.54 M
Operating CF
-4.65 M
Total Assets
4.65 M
Total Liabilities
4.58 M
Equity
70.70 K
D/E Ratio
12,345
7.54 %
Week
123.97 %
1 Month
65.13 %
3 Month
-19.57 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
2.95 M
Monthly Burn
1.55 M
Runway
0 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
4.31 K
52 Week Range
1.90 - 13.80
% held by Insiders
0.49 %
% held by Institutions
9.96 %
Enterprise Value
5.20 M
Total Shares
1.46 M
Short %
2.52 %
Float Shares
1.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CNS Pharmaceuticals, Inc.
154Total events
1Upcoming
25Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 1
Event history 153
Mar 2, 2026
Jul 15, 2025
▼Topline ReadoutBerubicinClinical Data
Reported Primary Analysis of Berubicin Monotherapy in 2nd line GBM
Glioblastoma Multiforme (GBM)source ↗
Apr 9, 2025
▼Topline ReadoutBerubicinClinical Data
Reported Primary Analysis of Berubicin Monotherapy in 2nd line GBM
Glioblastoma Multiforme (GBM)source ↗
Feb 21, 2025
2025
◆Timing GuidancePresentation
Plan to engage with regulators to design potential registration study in 2025
Glioblastoma Multiforme (GBM)source ↗
2025
◆FDA Feedback ReceivedFDA Meeting
Plan to engage with regulators to design potential registration study in 2025
Glioblastoma Multiforme (GBM)source ↗
2025
▲EMA OrphanBerubicinEx-US Regulatory
Upcoming filing in EU for Orphan Drug Designation
Glioblastoma Multiforme (GBM)source ↗
2025
◆Trial InitiationTrial
Plan to engage with regulators to design potential registration study for TPI 287
Glioblastoma Multiforme (GBM)source ↗
Q1 2025
◆Topline ReadoutBerubicinClinical Data
Topline data expected from Berubicin GBM study
glioblastoma multiforme (GBM)source ↗
2024
▲Enrollment CompleteBerubicinTrial
Berubicin pivotal trial fully enrolled with 252 subjects
Glioblastoma Multiforme (GBM)source ↗
Drug Pipeline Intelligence
D22
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal9
Drugs Scored0.2x
rNPV / MCap Top 21%
Micro Cap (rank 721 of 912)
Percentile RankCNS Pharmaceuticals, Inc. faces pipeline headwinds (22/100), with $503M risk-adjusted pipeline value, led by CTX-4430 in Acne Vulgaris (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX-4430 Small molecule | Acne Vulgaris | Phase 2 | NCT02385760 | 17% | $120M | COMPLETED | 124 | - | - | Aug 1, 2016 | - | Aug 2, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Berubicin Fast TrackOrphan | Glioblastoma Multiforme | — | 2025-07-15 | Did not a statistically significant difference in overall survival Read More | NASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than state Read More | |
Berubicin Fast TrackOrphan | Glioblastoma Multiforme | — | 2025-07-15 | Did not a statistically significant difference in overall survival Read More | NASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than state Read More | |
Berubicin Fast TrackOrphan | Glioblastoma Multiforme | — | 2025-07-15 | Did not a statistically significant difference in overall survival Read More | NASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than state Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNSP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNSP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNSPCNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
CNS Pharmaceuticals recently completed an oversubscribed $22.5 million financing, as discussed by CFO Steve O’Loughlin in a Virtual Investor segment. The financing reflects investor confidence in the company's strategic transformation and acquisition-focused approach. O’Loughlin emphasized the importance of institutional support for advancing the company's growth and creating long-term shareholder value.
Read more →CNSP▲ +6.7%on this news
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress
CNS Pharmaceuticals participated in a Virtual Investor CEO Connect segment where CEO Rami Levin discussed the company's recent $22.5 million financing and its strategic pivot. He outlined the progress made and the company's plans for pipeline development aimed at enhancing shareholder value. Levin emphasized key milestones for investors to monitor moving forward.
Read more →CNSP▼ -9.2%on this news
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
CNS Pharmaceuticals reported its first quarter 2026 financial results, highlighting a strategic transformation led by a new executive team. The company secured $22.5 million in financing to pursue acquisition opportunities for clinical-stage assets. Despite a net loss of approximately $4.9 million, the company aims to advance its pipeline and create long-term shareholder value.
Read more →CNSP▼ -9.8%on this news· ran to -23% by day 3shared move
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Oncotelic Therapeutics is progressing in the development of its intranasal nose-to-brain (N2B) delivery system aimed at improving CNS drug delivery, particularly for Alzheimer's disease and biodefense applications. The company has announced a strategic agreement with Lunai Bioworks to monetize its N2B delivery system for specific applications. Despite the innovative solutions being explored, challenges persist with the blood-brain barrier, resulting in a high failure rate for therapeutic candidates. The ongoing demand for effective CNS interventions underscores the importance of Oncotelic's technology in both civilian and biodefense contexts.
Read more →CNSP▼ -7.3%on this news· ran to -31% by day 3shared move
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Oncotelic Therapeutics is making strides in central nervous system (CNS) drug delivery by advancing technologies designed to bypass the blood-brain barrier (BBB). Their proprietary nose-to-brain (N2B) delivery system has garnered attention, particularly in the context of rising Alzheimer’s disease cases and biodefense needs. Recently, Oncotelic announced a strategic monetization with Lunai Bioworks concerning its N2B system, highlighting the growing demand for effective CNS drug delivery solutions. The emphasis on overcoming delivery challenges is seen as key to improving therapeutic outcomes for neurodegenerative diseases.
Read more →CNSP▲ +239.2%on this news
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
CNS Pharmaceuticals has announced a successful private placement financing, raising approximately $22.5 million from notable healthcare investors. The funds will be utilized to acquire clinical-stage assets aligned with the company's new corporate strategy. CNS aims to enhance its pipeline and create near-term value for patients and shareholders.
Read more →CNSP▼ -11.6%on this news· ran to -27% by day 3
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
CNS Pharmaceuticals has launched a new corporate strategy to develop a high-value pipeline in neurology and oncology. The newly formed executive team will focus on acquiring differentiated therapeutic assets, moving away from a singular focus on glioblastoma. The company plans to out-license legacy assets while prioritizing programs with strong clinical potential and unmet medical needs.
Read more →CNSP▼ -11.6%on this news· ran to -27% by day 3shared move
cnspharma.com NASDAQ: CNSP March 2026 Investor Presentation 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statem
CNS Pharmaceuticals has announced a strategic pivot under a new executive team aimed at repositioning the company for long-term success in neurology and oncology. The new strategy emphasizes disciplined capital allocation and a focus on high-value, unmet medical needs. A comprehensive review has led to the targeting of preclinical and clinical-stage programs that show significant commercial viability. Additional highlights include the potential out-licensing of legacy programs to unlock value for shareholders.
Read more →CNSPCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
CNS Pharmaceuticals has appointed Dr. Lynne Kelley as Chief Medical Officer, completing its executive leadership team. Dr. Kelley brings extensive experience in oncology and rare diseases, having successfully led numerous clinical programs and regulatory approvals globally. Her expertise is expected to drive the company's strategic growth and enhance its drug development pipeline.
Read more →CNSP▼ -5.8%on this news
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation
CNS Pharmaceuticals has appointed key executives to its leadership team to support its strategic transformation. The new appointments include Steven O'Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, all effective March 2, 2026. The company aims to enhance operational execution and drive value creation through disciplined growth and a focus on pipeline optimization.
Read more →CNSP▼ -5.8%on this newsshared move
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation
CNS Pharmaceuticals has appointed key executives to enhance its leadership team, aiming to drive the company's strategic transformation. Rami Levin, the new CEO, emphasizes a focus on disciplined growth and operational rigor. The new team, effective March 2, 2026, brings extensive experience in advancing clinical assets and executing strategic transactions.
Read more →CNSPCNS Pharmaceuticals Issues Letter to Shareholders - January 27, 2026
CNS Pharmaceuticals has issued a letter to shareholders from its new CEO, Rami Levin, outlining a strategic focus on pipeline optimization and value creation. Levin emphasizes the importance of addressing unmet medical needs and refining the development of their lead asset, TPI 287. The company aims to enhance its operational structure and ensure disciplined capital allocation to maximize shareholder returns.
Read more →CNSPCNS Pharmaceuticals Issues Letter to Shareholders
CNS Pharmaceuticals has issued a letter to shareholders from its new CEO, Rami Levin, outlining a strategic focus on pipeline optimization and value creation. Levin emphasizes a patient-first approach and the importance of refining their lead asset, TPI 287, to enhance its clinical potential. The company aims to strengthen its operational execution and maintain transparent communication with shareholders.
Read more →CNSP▼ -6.4%on this news
CNS Pharmaceuticals Announces CEO Transition
CNS Pharmaceuticals has announced the appointment of Rami Levin as the new CEO, succeeding John Climaco. Levin, an industry veteran with nearly 30 years of experience, is expected to lead the company through its next growth phase, focusing on the development of TPI 287, a promising anti-cancer drug. The transition aims to enhance the company's strategic direction and operational capabilities.
Read more →CNSPCNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals reported its third quarter 2025 financial results, highlighting progress with its lead candidate TPI 287 for glioblastoma treatment. The company has sufficient cash to fund operations into mid-2026 and is preparing for a Phase 2 trial. Early data suggests TPI 287 may effectively cross the blood-brain barrier, enhancing treatment options for patients.
Read more →CNSPCNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
CNS Pharmaceuticals has announced that three of its abstracts have been accepted for poster presentations at the Society of NeuroOncology's 30th Annual Meeting. The presentations will cover the activity of Berubicin against pediatric diffuse midline glioma, the evaluation of TPI 287 in a Phase 2 trial for glioblastoma, and results from a clinical trial comparing Berubicin and Lomustine in glioblastoma patients. The event will take place in Honolulu, HI from November 19-23, 2025.
Read more →CNSPCNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company will also hold one-on-one meetings with investors. Their drug candidate, TPI 287, has shown potential in treating CNS tumors and has been well-tolerated in clinical trials.
Read more →CNSP▼ -15.6%on this news
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals reported a net loss of $2.4 million for Q2 2025 but maintains a strong cash position of $12.1 million. The company is advancing its lead program, TPI 287, towards a Phase 2 study for glioblastoma, with promising clinical data suggesting its ability to cross the blood-brain barrier. The firm plans to engage the FDA regarding study design for TPI 287 in recurrent GBM.
Read more →CNSP▼ -16.4%on this news· ran to -29% by day 1shared move
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
CNS Pharmaceuticals, Inc. will present at the Webull Financial Corporate Connect Webinar Series on August 19, 2025. CEO John Climaco will discuss the company's advancements in developing treatments for primary and metastatic cancers affecting the brain and central nervous system. The presentation highlights the potential of their drug candidate TPI 287, which has shown promising clinical efficacy.
Read more →CNSP▼ -5.4%on this news
CNS Pharmaceuticals to Participate in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
CNS Pharmaceuticals participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference, where CEO John Climaco discussed his dedication to the company and its cancer treatment programs. The on-demand video is available on the company's website and virtualinvestorco.com. CNS Pharmaceuticals focuses on developing novel treatments for brain and central nervous system cancers.
Read more →CNSP▼ -10.7%on this news· ran to -24% by day 3shared move
CNS Pharmaceuticals Announces Reverse Stock Split
CNS Pharmaceuticals has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. This move aims to enhance the stock's market value while maintaining the same percentage interest for stockholders. The company continues to develop its anti-cancer drug candidate, TPI 287, which shows promise in treating various CNS tumors.
Read more →CNSP▼ -10.7%on this news· ran to -24% by day 3shared move
CNS Pharmaceuticals Announces Reverse Stock Split HOUSTON, TX (
CNS Pharmaceuticals has announced a 1-for-12 reverse stock split effective from July 22, 2025. This move is intended to support the company's listing on Nasdaq, as it consolidates shares and adjusts outstanding securities accordingly. The firm is actively developing TPI 287, an anti-cancer drug showing initial promise in treating CNS tumors. Although the reversal affects all shareholders uniformly, it raises some concerns regarding the company's stock performance.
Read more →CNSPNASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than state
CNSP is focusing on the development of TPI 287, a potential treatment for Glioblastoma Multiforme, supported by a robust financial position. The company has established a global clinical trial network aimed at accelerating CNS-focused trials. However, the latest analysis of Berubicin did not indicate a significant improvement in overall survival, raising concerns about its efficacy compared to existing treatments. The future of CNSP's operations may face uncertainties and risks that could affect anticipated outcomes.
Read more →CNSPCNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
CNS Pharmaceuticals participated in a Virtual Investor CEO Connect segment where CEO John Climaco discussed the company's lead program, TPI 287. He highlighted insights from the Longwood Healthcare Leaders Spring 2025 Meeting. TPI 287 is being developed for treating primary and metastatic cancers in the brain and has shown potential in clinical trials.
Read more →CNSPCNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
CNS Pharmaceuticals has launched a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, who discusses the treatment landscape for Glioblastoma Multiforme and the potential of TPI 287. This drug candidate aims to treat both primary and metastatic CNS tumors and has shown promising initial clinical efficacy. TPI 287 has been tested in over 350 patients and appears to have a strong safety profile.
Read more →CNSPCNS Pharmaceuticals’ Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
CNS Pharmaceuticals' Chief Medical Officer, Dr. Sandra Silberman, will present at the 2025 Brain Tumor Biotech Summit on TPI 287, a drug in development for glioblastoma. The presentation will highlight TPI 287's mechanism of action and its potential to cross the blood-brain barrier. The drug has shown promising clinical efficacy, including complete and partial responses in patients.
Read more →CNSPCNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals reported its Q1 2025 financial results, highlighting a net loss of $4.3 million and increased R&D expenses. The company is advancing its lead program, TPI 287, with plans to commence a Phase 2 study for glioblastoma by the end of 2025. CNS has a cash runway expected to last into the second half of 2026, bolstered by a recent public offering.
Read more →CNSP▼ -20%on this news· ran to -32% by day 1shared move
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNS Pharmaceuticals has announced the pricing of a public offering totaling $5 million, selling nearly 4 million shares at $1.265 each. The offering includes Series F Warrants with an exercise price of $1.14, which will be exercisable immediately. Proceeds from the offering will support working capital and corporate purposes, with closing expected shortly.
Read more →CNSP▲ +12.4%on this newsshared move
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
CNS Pharmaceuticals has acquired Orphan Drug Designation for TPI 287, a novel abeotaxane that shows potential in treating glioblastoma multiforme by crossing the blood-brain barrier. The FDA previously granted this designation, which provides various incentives for developing treatments for rare diseases. The company plans to begin patient enrollment for a Phase 2 study by the end of 2025.
Read more →CNSP▲ +9.7%on this news· ran to +24% by day 3
NASDAQ: CNSP April 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than stat
CNS Pharmaceuticals, trading as NASDAQ: CNSP, presented forward-looking statements regarding its drug development strategies and financial position. The company is focused on developing anti-cancer therapies for brain cancers, with TPI 287 as a lead candidate. While they have established a clinical development infrastructure, recent analyses of their Berubicin treatment have not shown significantly improved survival rates. Their financial position appears robust, allowing operations to continue into 2025.
Read more →CNSP▼ -5.1%on this news· ran to -19% by day 3
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNS Pharmaceuticals reported its financial results for 2024, highlighting a year of cash reserves to support operations. The company is advancing TPI 287, a promising treatment for glioblastoma multiforme (GBM), while also addressing the results of the Berubicin study, which did not meet its primary endpoint but showed safety and tolerability. The company plans to engage with the FDA regarding TPI 287's development.
Read more →CNSP▼ -51.8%on this news
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNS Pharmaceuticals announced the primary analysis of Berubicin for treating recurrent Glioblastoma Multiforme. While the results did not show a statistically significant improvement in overall survival compared to Lomustine, Berubicin demonstrated comparable outcomes in clinically relevant endpoints and a favorable safety profile, particularly with no cardiotoxicity. The company plans to continue investigating Berubicin's potential in this challenging cancer indication.
Read more →CNSPCNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
CNS Pharmaceuticals has announced a strong cash position of $14 million, which is expected to fund operations into 2026. The company is set to release primary data analysis for its lead drug, Berubicin, in the first half of 2025 and aims to start its TPI 287 clinical program by the end of the year. Maintaining its NASDAQ listing remains a priority as the company approaches key milestones.
Read more →CNSP▼ -10.5%on this news· ran to -43% by day 3
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on February 26, 2025. CEO John Climaco will discuss the company's innovative treatments for brain and CNS cancers. The event will also allow for one-on-one meetings with investors. A video webcast of the presentation will be available for registered attendees.
Read more →CNSP▼ -41.2%on this news· ran to -60% by day 3shared move
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
CNS Pharmaceuticals, Inc. participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO John Climaco highlighted key reasons for investment in the company. CNS is focused on developing novel treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, which shows promise in crossing the blood-brain barrier.
Read more →CNSPCNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
CNS Pharmaceuticals will present at the 6th Glioblastoma Drug Development Summit in Boston from February 18-20, 2025. Dr. Sandra Silberman will discuss the potential of novel formulations of anthracyclines and taxanes that may effectively cross the blood-brain barrier. The company’s lead drug, Berubicin, has shown efficacy in Phase 1 trials, and it has received Fast Track Designation from the FDA.
Read more →CNSP▲ +10.5%on this news
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
CNS Pharmaceuticals will present at the BIO CEO & Investor Conference on February 10, 2025. CEO John Climaco will discuss the company's advancements in developing treatments for brain and central nervous system cancers. The presentation will take place at 1:15 PM ET in New York, with opportunities for one-on-one meetings with management.
Read more →CNSP▲ +5.2%on this news
NASDAQ: CNSP January 2025 Forward Looking Statements 2 This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than st
CNS Pharmaceuticals is advancing its oncology pipeline with key developments for its lead program, Berubicin, focused on treating glioblastoma multiforme. The company reports that the clinical trial for Berubicin is fully enrolled, with primary analytical data expected in the first half of 2025. The drug has been well-tolerated by patients, showing no signs of cardiotoxicity, and has promising preliminary results regarding tumor shrinkage. Additionally, CNSP has in-licensed TPI 287, a novel drug aimed at treating brain malignancies, further enhancing its product offerings.
Read more →CNSPNASDAQ: CNSP
CNS Pharma is preparing for a transformative period in 2025, highlighted by its lead program, Berubicin, which is designed to cross the blood-brain barrier and is currently in pivotal trials. The company has also in-licensed TPI 287, enhancing its pipeline targeting glioblastoma. The ongoing developments aim to address significant unmet needs in treating this aggressive cancer. Data analysis for Berubicin is anticipated in the first half of 2025.
Read more →CNSPCNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
CNS Pharmaceuticals will host a Virtual Analyst & Investor Day on December 11, 2024, featuring discussions on glioblastoma multiforme (GBM) and their drug candidate Berubicin. Key Opinion Leaders will join CNS management to provide insights into the clinical development program. The event will be available via live webcast and replay.
Read more →CNSP▼ -7.6%on this news
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals presented updated results from its potentially pivotal study of Berubicin versus Lomustine for recurrent glioblastoma at the SNO 2024 meeting. The study, which has enrolled 252 patients, aims to demonstrate Berubicin's efficacy and safety. The primary endpoint is overall survival, with data expected in the first half of 2025. The FDA has granted Berubicin Fast Track and Orphan Drug Designations.
Read more →CNSP▲ +14.2%on this news
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
CNS Pharmaceuticals has announced that its abstract has been accepted for a poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation will cover a potentially pivotal trial comparing Berubicin and Lomustine for glioblastoma treatment. This event will take place from November 21-24, 2024, in Houston, TX.
Read more →CNSP▼ -11.6%on this newsshared move
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
CNS Pharmaceuticals reported its third quarter 2024 financial results, highlighting significant advancements in its drug pipeline, particularly with Berubicin for GBM. The company has strengthened its cash position to support operations through mid-2025 and has expanded its offerings with the in-licensing of TPI 287. Despite an increase in net loss and R&D expenses, the outlook remains positive as they prepare for pivotal study data in 2025.
Read more →CNSPCNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
CNS Pharmaceuticals announced participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, a leading neuro-oncologist. The discussion focused on the unmet needs in glioblastoma multiforme and the potential of Berubicin, CNS's lead drug candidate, to address these challenges. Berubicin is notable for its ability to cross the blood-brain barrier, which could enhance treatment efficacy.
Read more →CNSP▼ -11.3%on this newsshared move
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
CNS Pharmaceuticals has been granted an exception by the Nasdaq Hearings Panel, allowing the company until March 11, 2025, to regain compliance with the minimum bid price requirement. This development is significant for CNS as it continues to focus on its pipeline of anti-cancer drug candidates, including Berubicin, which targets aggressive brain cancers.
Read more →CNSP▼ -10%on this news
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules HOUSTON
CNS Pharmaceuticals, Inc. has announced a registered direct offering of common stock, priced at $0.17 per share, to raise approximately $3 million. The offering involves the sale of 17,647,060 shares and is expected to close on or about October 24, 2024. The proceeds will primarily be used for working capital and general corporate purposes, indicating the company's ongoing focus on advancing its oncology pipeline, including its lead candidate Berubicin. This funding move aims to support their initiatives in developing novel treatments for cancers affecting the brain and nervous system.
Read more →CNSPCNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
CNS Pharmaceuticals participated in a Virtual Investor KOL Connect segment featuring its management team and Dr. Samuel Goldlust, a leading Neuro-Oncologist. The discussion highlighted the unmet needs in glioblastoma multiforme and the potential of their lead drug candidate, Berubicin, which is designed to treat aggressive brain cancers. The event underscores CNS's commitment to advancing treatments for central nervous system cancers.
Read more →CNSP▲ +11.1%on this newsshared move
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
CNS Pharmaceuticals will participate in the 2024 Healthcare Virtual Summit hosted by Maxim Group LLC. CEO John Climaco is scheduled for a fireside chat on October 16, 2024. The summit will feature various biotechnology and healthcare companies, offering presentations and discussions. CNS Pharmaceuticals focuses on developing treatments for brain and central nervous system cancers.
Read more →CNSPCNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
CNS Pharmaceuticals, Inc. will present at the 24th Annual Biotech in Europe Forum on September 25, 2024. CEO John Climaco will lead the presentation in Basel, Switzerland, and will also hold one-on-one meetings with investors. The event highlights the company's commitment to developing novel cancer treatments, particularly for brain and CNS cancers.
Read more →CNSPCNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
CNS Pharmaceuticals has announced that it has regained compliance with Nasdaq's equity requirement as of September 10, 2024. This compliance is subject to a one-year monitoring period by Nasdaq. The company specializes in developing treatments for brain and central nervous system cancers, with its lead drug candidate, Berubicin, showing promise in treating aggressive forms of brain cancer.
Read more →CNSPCNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO John Climaco will lead the presentation and participate in one-on-one meetings with investors. A video webcast of the presentation will be available on-demand starting September 9, 2024.
Read more →CNSP▼ -6.2%on this news
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
CNS Pharmaceuticals will participate in the LIVE! with Webull Corporate Connect webinar on August 28, 2024. CEO John Climaco is set to discuss recent corporate events and developments. The company specializes in novel treatments for brain and central nervous system cancers, with its lead drug candidate, Berubicin, showing promise in treating glioblastoma multiforme.
Read more →CNSP▲ +5.8%on this news· ran to +19% by day 1shared move
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
CNS Pharmaceuticals will host a Virtual Investor CEO Connect segment on August 26, 2024, featuring CEO John Climaco. The event will include a presentation followed by a live Q&A session where participants can submit questions. A replay of the webcast will be available for 90 days after the event.
Read more →CNSPCNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
CNS Pharmaceuticals reported its Q2 2024 financial results, highlighting the completion of enrollment in its pivotal Berubicin trial for glioblastoma multiforme (GBM). The company has also in-licensed TPI 287, aiming to advance it into a registration study for recurrent GBM. CNS expects topline results from the Berubicin trial in early 2025 and has received FDA Fast Track Designation for the drug.
Read more →CNSPCNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
CNS Pharmaceuticals has entered into an exclusive license agreement with Cortice Biosciences for TPI 287, a novel drug candidate aimed at treating glioblastoma multiforme (GBM). This in-licensing is expected to complement the ongoing Berubicin program. TPI 287 has demonstrated promising clinical efficacy and safety in prior studies, and the company plans to seek FDA guidance for its further development.
Read more →CNSPCNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies Strategic in-license from Cortice Bioscience is highly syne
CNS Pharmaceuticals has entered into an exclusive licensing agreement with Cortice Biosciences for TPI 287, a potential blood-brain barrier permeable treatment targeted at glioblastoma multiforme (GBM). This addition aims to bolster CNS's treatment capabilities alongside its Berubicin program. TPI 287 has already demonstrated a promising safety and efficacy profile in prior studies involving over 350 patients. The company is set to advance TPI 287 through further clinical development and regulatory submission with the support of its established neuro-oncology networks.
Read more →CNSPCNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
CNS Pharmaceuticals announced that CEO John Climaco will participate in the Virtual Investor Closing Bell Series on June 17, 2024. During the event, he will provide a corporate overview and answer live questions from participants. The presentation will be available via a live webcast and can be accessed later for 90 days.
Read more →CNSPCNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement HOUSTON
CNS Pharmaceuticals, Inc. announced the pricing of a registered direct offering and a concurrent private placement, signaling a potential influx of funds. The company aims to sell 1,425,000 shares at a combined price of $1.39 per share, with the total gross proceeds expected to reach around $1.98 million. The funds are intended for working capital and general corporate purposes, with the transaction expected to close on or about July 5, 2024. The common stock will be issued under an effective registration statement filed with the SEC.
Read more →CNSPCNS Pharmaceuticals to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
CNS Pharmaceuticals will present at the Alliance Global Partners' 2024 Healthcare Company Showcase on May 21, 2024. CEO John Climaco will participate in a fireside chat, which will be available via live webcast. The company focuses on developing treatments for brain and central nervous system cancers, including its lead candidate, Berubicin.
Read more →CNSPCNS Pharmaceuticals Reports First Quarter 2024 Financial Results
CNS Pharmaceuticals reported its financial results for Q1 2024, highlighting the completion of enrollment in a pivotal study for Berubicin, targeting glioblastoma multiforme (GBM). The company anticipates topline data in the first half of 2025. Financially, CNSP reduced its net loss compared to the previous year, aided by decreased research and administrative expenses.
Read more →CNSPCNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the
CNS Pharmaceuticals has completed enrollment in its pivotal study evaluating Berubicin for glioblastoma multiforme (GBM) and expects topline data in the first half of 2025. The company reported a reduced net loss of approximately $3.5 million for Q1 2024, down from $4.9 million in the same period last year. CNS has received both Fast Track and Orphan Drug Designation from the FDA, indicating progress and potential for expedited review. Despite some financial losses, the company's leadership expressed strong commitment to advancing treatment options for GBM patients.
Read more →CNSPCNS Pharmaceuticals to Present at the LSX World Congress 2024
CNS Pharmaceuticals, Inc. will present at the LSX World Congress 2024 on April 29, 2024, at 4:15 PM GMT+1 in London. CEO John Climaco will lead the presentation, and the company will also hold one-on-one meetings with registered investors. The event is a key opportunity for networking within the biotech sector.
Read more →CNSPCNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNS Pharmaceuticals will host a Virtual Investor Lunch Break event on April 23, 2024, featuring CEO John Climaco. The presentation will cover the company's corporate overview and business outlook, along with a live Q&A session for investors. This event highlights CNSP's commitment to transparency and investor relations.
Read more →CNSPINVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP NASDAQ: CNSP This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements containe
CNS Pharmaceuticals is progressing with its anti-cancer drug Berubicin, specifically targeting glioblastoma multiforme (GBM), an aggressive and treatment-resistant brain cancer. The company reported that the ongoing pivotal clinical trial is fully enrolled, with no cardiotoxicity reported in earlier trials. An independent Data Safety Monitoring Board has advised continuing the trial without modifications, indicating promising efficacy. Final top-line data is anticipated in the first half of 2025, which could lead to potential FDA approval.
Read more →CNSPCNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
CNS Pharmaceuticals reported its financial results for 2023, highlighting significant progress in its lead program, Berubicin, which successfully passed an interim futility analysis. The study for Berubicin, aimed at treating glioblastoma multiforme (GBM), has completed enrollment, with topline data expected in the first half of 2025. Despite a net loss increase, the company secured $4 million in funding and received FDA designations to expedite the drug's development.
Read more →CNSPCNS Pharmaceuticals to Present at Two Investor Conferences in April
CNS Pharmaceuticals, Inc. will present at two investor conferences in April 2024. CEO John Climaco will discuss the company's developments in cancer treatments, including their lead drug candidate, Berubicin. The presentations will take place in New York City, with opportunities for one-on-one meetings with investors. Live webcasts of the events will be available.
Read more →CNSPCNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with rec
CNS Pharmaceuticals has reported its financial results for the full year 2023, highlighting significant achievements in the development of Berubicin for treating glioblastoma multiforme (GBM). The company successfully completed a pre-planned interim futility analysis, receiving a recommendation to continue the trial without modifications, with topline data expected in 2025. Despite a net loss increase to approximately $18.9 million and rising research expenses, the company secured $4 million through a public offering, aiming to support its ongoing operations and drug development. CNS is committed to addressing the significant unmet medical needs associated with GBM.
Read more →CNSPCNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
CNS Pharmaceuticals has announced the pricing of a public offering totaling $4 million, with shares priced at $0.30 each. The offering will involve the issuance of Series A and B Warrants and is expected to close around February 1, 2024. Proceeds will be used for the CNS-201 trial and other R&D efforts.
Read more →CNSPBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
CNS Pharmaceuticals has appointed Amy Mahery to its Board of Directors, effective after a financing round. Mahery, currently the Chief Commercial Officer at Roivant Sciences, brings over 20 years of experience in the biopharmaceutical industry. Her expertise in commercialization is expected to support the advancement of CNS's lead drug candidate, Berubicin, towards potential regulatory approval.
Read more →CNSPCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
CNS Pharmaceuticals has completed enrollment in a pivotal study for Berubicin, aimed at treating glioblastoma multiforme (GBM). The study, involving 247 patients across multiple countries, compares Berubicin to Lomustine. The FDA has granted Fast Track Designation for Berubicin, enhancing its development process. The DSMB has recommended continuing the trial based on positive interim results.
Read more →CNSPCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
CNS Pharmaceuticals announced a positive interim analysis from the independent Data Safety Monitoring Board (DSMB) regarding its trial of Berubicin for glioblastoma multiforme. The DSMB recommended continuing the trial without modifications, indicating that Berubicin's efficacy is comparable to the standard treatment, Lomustine. Enrollment for the trial is expected to conclude in early Q1 2024.
Read more →CNSPCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin Independent DSMB recommends continuing clinical trial of Berubicin without modification Enro
CNS Pharmaceuticals has announced a successful interim analysis of its trial for Berubicin, a treatment for glioblastoma multiforme. The independent Data Safety Monitoring Board (DSMB) recommended that the study continues without modification, indicating that Berubicin meets efficacy and safety standards. The trial, which compares Berubicin to Lomustine, is on track to complete in early Q1 2024. CNS has also received Fast Track and Orphan Drug Designations from the FDA for Berubicin, highlighting the drug's potential in a significant unmet medical need.
Read more →CNSPHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
CNS Pharmaceuticals is advancing its treatment for glioblastoma with Berubicin, a chemotherapy drug that effectively penetrates the blood-brain barrier. The company has enrolled 200 patients in a global study comparing Berubicin to the standard treatment Lomustine. Interim results are promising, suggesting potential improvements in overall survival for patients treated with Berubicin. The management team, led by CEO John Climaco, brings extensive experience in oncology and drug development.
Read more →CNSPCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
CNS Pharmaceuticals presented updated safety data for Berubicin at the SNO Annual Meeting. The drug is being evaluated in a pivotal study for glioblastoma multiforme, with interim efficacy results expected in December 2023. The safety data showed comparable demographics and adverse events between Berubicin and Lomustine, though more withdrawals occurred in the Lomustine group.
Read more →CNSPCNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
CNS Pharmaceuticals is set to release interim data for Berubicin, a drug targeting glioblastoma, by the end of the year. Berubicin has shown promise in earlier trials, demonstrating a 44% clinical response rate. The drug is designed to penetrate the blood-brain barrier, addressing a significant challenge in treating this aggressive cancer. The ongoing trial compares Berubicin to Lomustine, with results expected soon.
Read more →CNSPCNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
CNS Pharmaceuticals reported its Q3 2023 financial results, highlighting significant progress in its pivotal study of Berubicin for glioblastoma treatment. Enrollment has reached 239 patients, with full enrollment expected by December 2023. The company anticipates topline data from an interim analysis soon and has raised $2.6 million to support ongoing operations.
Read more →CNSPCNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Enrollment numbers rise to 239 in ongoin
CNS Pharmaceuticals reported its financial results for the third quarter of 2023, highlighting significant progress in the enrollment of patients for its pivotal study of Berubicin, which has reached 239 patients. The company anticipates completing enrollment by December 2023 and expects to release interim analysis data within the same month. Financially, CNS experienced a net loss of approximately $4.5 million during this quarter, attributed to increased research and development costs. The FDA has granted Berubicin Fast Track and Orphan Drug Designations, potentially accelerating its development timeline.
Read more →CNSPCNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
CNS Pharmaceuticals will participate in the Virtual Investor Ask the CEO Conference on October 24, 2023, at 4:00 PM ET. CEO John Climaco will address investor questions live, providing a platform for direct engagement. A webcast of the event will be available, along with a replay for those unable to attend live.
Read more →CNSPGlioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure – CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
CNS Pharmaceuticals is advancing Berubicin, a chemotherapy drug aimed at treating glioblastoma, a highly aggressive brain cancer. With the ability to penetrate the blood-brain barrier, Berubicin targets cancer cells directly, offering hope for improved patient outcomes. The drug has received FDA Orphan Drug and Fast Track Designations, and a phase 2 clinical trial is currently underway.
Read more →CNSPCNS Pharmaceuticals’ (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
CNS Pharmaceuticals has enrolled 229 patients in its pivotal study of Berubicin for recurrent glioblastoma, nearing its target of 243. The company anticipates completing enrollment by year-end and plans to report interim analysis results soon. Berubicin has received FDA Fast Track and Orphan Drug Designations, enhancing its development prospects.
Read more →CNSPCNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
CNS Pharmaceuticals has successfully enrolled 200 patients in its pivotal study of Berubicin for recurrent glioblastoma multiforme (GBM). The study aims to demonstrate the drug's effectiveness compared to the standard treatment, Lomustine. Interim analysis results are anticipated by the end of 2023, with ongoing enrollment at multiple clinical sites across several countries.
Read more →CNSPCNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CNS Pharmaceuticals will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. CEO John Climaco will lead the presentation, which will be accessible via a live webcast. The company is focused on developing treatments for brain and central nervous system cancers, including its lead candidate, Berubicin.
Read more →CNSPCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals presented updated results from its ongoing pivotal study of Berubicin for treating recurrent Glioblastoma Multiforme (GBM) at the 2023 SNO/ASCO CNS Cancer Conference. The study has enrolled 151 patients, with promising safety and efficacy data reported. The company anticipates releasing interim results by year-end, which will assess Berubicin's effectiveness compared to Lomustine.
Read more →CNSPCNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
CNS Pharmaceuticals reported its Q2 2023 financial results, highlighting significant progress in its Berubicin study for glioblastoma. The company has enrolled 75% of expected patients and anticipates topline results from an interim analysis by year-end. Despite a net loss increase, CNS remains focused on operational efforts and upcoming milestones.
Read more →CNSPCNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study eva
CNS Pharmaceuticals has reported its financial results for Q2 2023 and updated on the progress of its pivotal study evaluating Berubicin for glioblastoma. Approximately 75% of the expected patients have been enrolled, with promising updates anticipated soon. The CEO expressed optimism about upcoming milestones, including a topline interim analysis expected by the end of Q4 2023. However, the company has also noted an increase in net loss and unpredictable costs related to ongoing clinical trials.
Read more →CNSPCNS Pharmaceuticals to Present at Benzinga’s Virtual Biotech Conference
CNS Pharmaceuticals, a biopharmaceutical company focused on cancer treatments, announced that its CEO, John Climaco, will participate in a fireside chat at Benzinga's Virtual Biotech Conference on August 3, 2023. The event aims to highlight leading biotech companies and will be available via a live webcast. CNS is known for its lead drug candidate, Berubicin, which targets brain and CNS cancers.
Read more →CNSPCNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
CNS Pharmaceuticals has reported significant progress in its clinical trial for Berubicin, aimed at treating glioblastoma multiforme. With 180 patients enrolled across 46 sites, the company anticipates completing enrollment by the end of 2023. An interim analysis is expected to yield topline data before year-end, reflecting the study's potential impact on patient survival.
Read more →CNSPCNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
CNS Pharmaceuticals announced that its abstract has been accepted for a poster presentation at the 2023 SNO/ASCO CNS Cancer Conference. The presentation will focus on preliminary results from a trial of Berubicin, a drug designed to treat glioblastoma multiforme. The conference will take place from August 10-12, 2023, in San Francisco.
Read more →CNSPCNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM continues to rapidly progress t
CNS Pharmaceuticals reported its first quarter financial results and provided an update on the ongoing clinical trial for Berubicin, a treatment for glioblastoma multiforme (GBM). The company successfully enrolled over 100 patients in the trial, with plans to report interim analysis results expected in Q3 2023. Recent appointments to the Board of Directors aim to strengthen its operational capabilities. However, the company also reported increased financial losses and higher expenses compared to the previous year.
Read more →CNSPBettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors Brings over 30 years of significant biopharmaceutical industry experience and proven clinical d
CNS Pharmaceuticals announced the appointment of Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director. With over 30 years in the biopharmaceutical industry, Dr. Cockroft adds significant clinical development and operational expertise to the board. Her prior roles include Chief Medical Officer and Vice President of Clinical Research at various biopharmaceutical firms, providing her with a wealth of experience in accelerating drug development processes. Her addition is intended to bolster the company's strategy for advancing their lead oncology drug, Berubicin, towards approval.
Read more →CNSPCNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licens
CNS Pharmaceuticals has appointed Faith L. Charles, JD, as the new Chair of its Board of Directors. With over 30 years of experience in the life sciences sector and expertise in corporate governance, Ms. Charles is expected to significantly contribute to the company’s clinical development and growth strategies. CNS Pharmaceuticals focuses on advancing treatments for brain cancers, including glioblastoma multiforme, and aims to improve conditions for patients in this area. Charles has held leadership roles at multiple biotech firms and has been recognized for her contributions to the industry.
Read more →CNSPCNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price HOUSTON, TX (
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price HOUSTON, TX (November 30, 2022) - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of n
Read more →CNSPProspectus Summary This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. Yo
This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the "Risk Factors"
Read more →CNSPCNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today ann
Read more →CNSPCNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Gl
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme ("GBM") Enrollment progressing wit
Read more →CNSPCNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Recent approvals of Potentially Pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive p
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update approvals of Potentially Pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment for Berubicin to be used in additional oncolog
Read more →CNSPCNS Digital Therapeutics Market to grow at a 31.6% CAGR from 2022 to 2030 - MDC Research
Pune, April 19, 2022 (GLOBE NEWSWIRE) -- The CNS digital therapeutics market is driven by increasing prevalence of neurological disorders, the growing geriatric population that in turn increases the prevalence of diseases that is linked more to old age. Moreover, digital therapeu
Read more →CNSPCNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update 2021 marked by operational advancements on clinical and regulatory fronts Company continues to execute progression of lead progra
CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update 2021 marked by operational advancements on clinical and regulatory fronts Company continues to execute progression of lead program, Berubicin, in ongoing potentially pivotal global cli
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP January 2022 CNS phar m ac e u t ical s 2 Forward - Looking Statements This presentation incorporates information from mat
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP January 2022 CNS phar m ac e u t ical s 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking st
Read more →CNSPCNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON, TX (
CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON, TX (January 6, 2022) - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatm
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP December 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP December 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statemen
Read more →CNSPCNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme
LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces
Read more →CNSPCNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook Recently granted FDA Fast Track Designation for Berubicin for treatment of recurrent Glioblastoma Multiforme (GBM) provides
CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook Recently granted FDA Fast Track Designation for Berubicin for treatment of recurrent Glioblastoma Multiforme (GBM) provides an accelerated pathway to potential approval and commerci
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP July 2021 CNS pharmaceuticals Forward - Looking Statements This presentation incorporates information from materials filed
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP July 2021 CNS pharmaceuticals Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . A
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP MAY 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials file
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP MAY 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements .
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP MARCH 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials fi
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP MARCH 2021 CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP FEBRUARY 2021 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the S
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP FEBRUARY 2021 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statemen
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP JANUARY 2021 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SE
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP JANUARY 2021 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statement
Read more →CNSPCNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that
Read more →CNSPCNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering HOUSTON (
Announces Pricing of $10.0 Million Public Offering HOUSTON (Dec. 23, 2020) - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and c
Read more →CNSPProspectus Summary This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our common stock.
This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read this entire prospectus carefully, including the "Risk Factors
Read more →CNSPwww.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contain
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 Nasdaq: CNSP CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained h
Read more →CNSPCNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that
Read more →CNSPCNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, toda
Read more →CNSPCNS Pharmaceuticals Announces US Drug Manufacturing Milestones
Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system
Read more →CNSPAMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (" Amendment ") is entered into effective as of
AMENDMENT TO EMPLOYMENT AGREEMENT ("Amendment") is entered into effective as of September 1, 2020 and serves to amend the Employment Agreement entered into by and between CNS Pharmaceuticals, Inc., a Nevada corporation ("Company"), and John Climaco ("Executive"), on September
Read more →CNSPCNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin HOUSTON
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin HOUSTON, June 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments
Read more →CNSPCNS Announces Common Stock Will Resume Trading on the NASDAQ on
Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020 HOUSTON, May 27 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and met
Read more →CNSPCNS Provides Update on Development Agreement for WP1122 HOUSTON, May 27 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development
CNS Provides Update on Development HOUSTON, May 27 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and centr
Read more →CNSPCNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information HOUSTON, May 18 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializin
CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information 18 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic ca
Read more →CNSPCNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results Company to Host Business Update Conference Call Today at 4:30 p.m. ET HOUSTON (
Announces Business Highlights and 2019 Fourth Quarter Financial Results to Host Business Update Conference Call Today at 4:30 p.m. ET HOUSTON (Mar. 12, 2020) - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the d
Read more →CNSPNasdaq: CNSP WWW.CNSPHARMA.COM 2100 West Loop South Suite 900 Houston, TX 77027 (800) 946 - 9185 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains
Nasdaq: CNSP WWW.CNSPHARMA.COM 2100 West Loop South Suite 900 Houston, TX 77027 (800) 946 - 9185 CNS pharmaceuticals 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained he
Read more →CNSPCNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline HOUSTON, TX
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline TX Jan. 13, 2020 - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain today announ
Read more →CNSPCNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option HOUSTON, TX
Pharmaceuticals Announces Full Exercise of Over-Allotment Option TX November 21, 2019 - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of the issuanc
Read more →CNSPCNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock HOUSTON, TX
Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock HOUSTON, TX - November 13, 2019 - CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors,
Read more →Competitive Position
How CNSP ranks across every disease it competes inCompetitive Position is a premium feature
See how CNSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial